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Abstract: Because of the antimicrobial resistance crisis, lectins
are considered novel drug targets. Pseudomonas aeruginosa
utilizes LecA and LecB in the infection process. Inhibition of
both lectins with carbohydrate-derived molecules can reduce
biofilm formation to restore antimicrobial susceptibility. Here,
we focused on non-carbohydrate inhibitors for LecA to
explore new avenues for lectin inhibition. From a screening
cascade we obtained one experimentally confirmed hit, a cat-
echol, belonging to the well-known PAINS compounds.
Rigorous analyses validated electron-deficient catechols as
millimolar LecA inhibitors. The first co-crystal structure of
a non-carbohydrate inhibitor in complex with a bacterial lectin
clearly demonstrates the catechol mimicking the binding of
natural glycosides with LecA. Importantly, catechol 3 is the
first non-carbohydrate lectin ligand that binds bacterial and
mammalian calcium(II)-binding lectins, giving rise to this
fundamentally new class of glycomimetics.
Introduction
Glycoconjugates on the cell surface of host tissues serve as
recognition patterns for microbial carbohydrate-binding pro-
teins, lectins, in the initial steps of an infection with
a pathogen.[1] The co-evolution between host glycoconjugates
and pathogen receptors resulted in the ability of lectins to
decipher the three-dimensional structure of complex
branched oligosaccharides, referred to as “glycocode”.[2]
Among pathogens, Pseudomonas aeruginosa is an opportun-
istic Gram-negative bacterium inter alia responsible for
pneumonia in immunocompromised patients, those suffering
from cystic fibrosis (CF), or patients under ventilation.[3] P.
aeruginosa starts forming a biofilm on its colonization site to
shield the bacterium from antimicrobial treatment and the
immune response and thus hampers combating the bacteria.
Host recognition, tissue adhesion and biofilm formation of P.
aeruginosa are mediated by two lectins: d-galactose-specific
and l-fucose/d-mannose-specific LecA and LecB, respective-
ly.[4] Both lectins are virulence factors and have been
considered as targets for the development of carbohydrate-
based anti-infective compounds and for the delivery of
antibiotics via carbohydrate targeting moieties.[5] LecA is of
special interest because of its ability to damage cell mem-
branes and to facilitate bacterial cell internalization.[6]
LecA is a homotetramer containing one calcium ion in the
carbohydrate-binding site coordinating amino acids and
galactosides (Figure 1A,B).[7] The target of this lectin is likely
the globotriaosylceramide glycolipid that presents the Gala1-
4Gal epitope.[8] The relatively low affinity for galactose or
galactobiose (Kd = 50 mM) is overcome by high avidity with
divalent or multivalent ligands that can cross-link the
neighbouring binding sites (Kd = 1–20 nM).
[5a, 9] However,
because of the presence of a hydrophobic surface nearby
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the galactose-binding site, monovalent galactosides with
aromatic aglycons demonstrated high affinity for the lectin
in the low micromolar range.[10] Recently, we reported an
epoxide-carrying galactoside that binds covalently to a cys-
teine residue present in the carbohydrate-binding site of
LecA.[11]
Targeting LecA is a promising way to counteract P.
aeruginosa infections. The chemical properties of the binding
pocket of LecA were used as an inspiration for the synthesis
of many compounds, all maintaining the presence of a gal-
actose residue for the primary calcium-dependent binding
site.[5a,e,12] The development of non-carbohydrate mimics
would be an alternative strategy, opening a large chemical
space for novel inhibitors. Indeed, since carbohydrate-protein
interactions are mostly governed by a complex arrangement
of hydrogen bonds and hydrophobic contacts, the success of
non-carbohydrate analogues is challenging. Non-carbohy-
drate glycomimetics were obtained for the model plant lectin
Concanavalin A[13] and virtual screening resulted in ligands
with higher affinities than the natural ligand mannose.[14]
Apart from this work on a model lectin, only C-type lectins,
that is, calcium-dependent animal lectins with roles in
inflammation and immunity, have been targeted. Several
compounds for the selectins have been obtained.[12, 15] Glyco-
mimetics based on a shikimic acid scaffold have shown good
inhibitory activity against the C-type lectin DC-SIGN.[16] The
presence of a calcium ion is therefore a promising factor for
a glycomimetic strategy against LecA.
Virtual screening is a powerful technique to identify
potential ligands from large chemical databases.[17] Therefore,
this approach was applied to screen the National Cancer
Institute (NCI) Diversity IV database for identifying non-
carbohydrate ligands directed to the galactose binding site of
LecA. The best virtual screening hits were experimentally
tested in a competitive binding assay based on fluorescence
polarization,[18] identifying catechol-containing compounds as
binder. Further, catechols were confirmed in orthogonal
biophysical methods: a thermal shift assay (TSA), ligand- and
protein-observed 19F (PrOF) and 1H-15N TROSY NMR
spectroscopy, surface plasmon resonance (SPR) and X-ray
crystallography was employed to elucidate their binding
modes to LecA. This work demonstrates the first example of
a novel group of non-carbohydrate glycomimetic compounds
targeting a bacterial lectin, which can be subsequently
developed into a novel class of LecA inhibitors.
Figure 1. A) Crystal structure of the homotetrameric LecA in complex with galactose (PDB code: 1OKO). B) View of calcium-ion dependent
galactose coordination in the carbohydrate-binding site of LecA. C/D) Shown are docking poses of five catechol-containing compounds from the
60 best virtual screening hits. Compound b is identical to 21 in Table 2.
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Results and Discussion
Virtual Screening of Ligands for LecA from NCI and Validation of
Catechol-Containing Hits in a Competitive Binding Assay
A docking protocol was designed using Glide[19] and the
1.5 c resolution crystal structure of LecA in complex with
a galactoside (PDB code 3ZYH).[10a] After internal validation
with ligands of known structures and affinities, the E-model
score function was selected for ranking of orientations
together with MM-GBSA[20] for ranking of energies (Fig-
ure S1). In total 1597 molecules from the National Cancer
Institute (NCI) diversity set IV were docked into the binding
site of LecA. Only those poses presenting a minimum of four
contacts in the site, that is, hydrogen bonds and coordination
to the calcium ion, were retained and ranked based on MM-
GBSA rescoring function which resulted in the top 60 poses
(Table S1). Those poses with at least two contacts to the
calcium ion were manually clustered according to their
similarity in binding mode into 15 groups and ranked as
a function of their lower energy pose. We identified the 10 top
clusters shown in Figure S2 that illustrate the encountered
variety of chemical space. Interestingly, clusters 1, 5 and 6
corresponded to analogs of nucleotides, binding to LecA
through 5-membered furanose rings. Other molecules bound
to the calcium ion through glycerol side chains (cluster 3),
sulfate groups (cluster 4) or a carboxylate (cluster 9). Of
special interest was cluster 2 with five molecules (Figure 1C)
that have a catechol motif to coordinate to the calcium ion
with the two vicinal oxygen atoms in a very conserved
geometry (Figure 1D). Finally, the lowest energy hit, 4-
isobutyryl catechol (compound b in Figure 1C, 21 in Table 2),
allows coordination to the calcium ion and an appropriate
balance of hydrogen bonds and hydrophobic contacts that
mimics the binding of galactose (see Figure S3).
Initially, 40 compounds derived from virtual screening
were selected based on structural diversity (Table S1),
purchased and screened in the established competitive bind-
ing assay based on fluorescence polarization at a single
concentration of 3.3 mM. Among the 40 compounds tested, 4-
isobutyryl catechol (b in Figure 1C, compound 21 in Table 2)
was identified as weak inhibitor (approx. 10% inhibition at
3.3 mM). It was the only molecule able to displace the
fluorescent galactoside ligand in this assay. Therefore, both
virtual and experimental screening suggest the catechol as
a new scaffold for LecA.
Experimental Screening of a Catechol Library
Despite the fact that some catechols are approved drugs,
for example, the b1-adrenergic agonist dobutamine or the
antibiotic cefiderocol, this class of compounds is well known
as frequent hitter and pan-assay interference compounds
(PAINS).[21] Catechols are prone to oxidation into highly
reactive quinones, which are reactive towards nucleophiles
and may lead to an unspecific interaction with proteins.[22]
However, the concept of a general exclusion of PAINS has
been recently questioned based on extensive analysis of
publicly available assay data[23] and a case-to-case consider-
ation using orthogonal assay activity has been stated neces-
sary.
The structure–activity relationship of catechols was fol-
lowed up by purchasing 29 further commercial catechols with
different substitution patterns and biophysical analysis using
various orthogonal methods (Table 1, Table 2). Unsubstituted
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DT [K] Efficiency [%]
at 1 mM
CSP of W42 [ppm]
1 120-80-9 H H inconcl. none @4.5 5.2 n.s.
2 4018-65-9 Cl H inconcl. none – 2.4 n.s.
3 67984-81-0 CN H 23:2 23:2 +1.8 20.6 0.045
4 363-52-0 F H inconcl. none – 1.3 n.s.
5 488-17-5 Me H inconcl. none none 8 0.055
6 14235-77-9 CH2OH H inconcl. 11:4 none 13.8 0.035
7 2144-08-3 OH CHO inconcl. inconcl. @3.3 17.2 n.s.
8 2138-22-9 H Cl inconcl. none – 2.5 n.s.
9 17345-61-8 H CN 4:1 7:2 +0.5 6.1 0.030
10 367-32-8 H F inconcl. none – 2.6 n.s.
11 452-86-8 H Me inconcl. none @11.0 6.9 n.s.
12 3316-09-4 H NO2 37:1 33:2 autofluor. 56.1 0.065
13 98-29-3 H tert-butyl inconcl. none @15.4 7.9 0.130
14 331-39-5 H E-CHCHCO2H inconcl. none – 7.3 n.s.
15 3843-74-1 H E-CHCHCO2Me inconcl. none – 7.8 0.045
16 133550-30-8 H E-CHC(CN)CONHBn inconcl.* inconcl.* – 15.8 at 0.5 mM n.s.
Protein-observed 19F (PrOF) NMR spectroscopy was performed with 5FW-LecA. FP averages and std. dev. from 3 experiments, TSA averages from two
experiments, *= tested at 25 % DMSO, 2ME =2-mercaptoethanol, CSP= chemical shift perturbation, n.s. = not significant, std. dev. <0.03 ppm.
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catechol 1 and various derivatives carrying electron-donating
or -withdrawing substituents in different positions were
obtained (2–30) among which are fourteen acylated catechols
(17–30, including the hit 4-isobutyryl catechol 21).
All compounds were tested in a modified competitive
binding assay with a Cy5 dye conjugated to a galactoside S7
(synthesis of S7 see Scheme S1, binding of S7 to LecA see
Figure S4). This change in fluorescent dye was necessary to
circumvent spectral overlap of some catechols with the
previously used fluorescein conjugate.[18] After 1 h incubation,
various catechols bearing electron-withdrawing substituents
showed a weak inhibition of LecA. Surprisingly, the polar-
ization measured for some of the tested compounds has
changed dramatically after extended incubation (16 h). While
some catechols showed a constant inhibition over time, in
particular catechols bearing electron-donating substituents
such as tert-butyl or methyl groups showed the strongest
increase in inhibition.
To avoid the false-positive detection of an apparent
inhibition due to an unspecific reactivity of potentially formed
quinones, 2-mercaptoethanol was added to the competitive
binding assay as an agent to trap those reactive species at
equimolar concentration to the highest catechol concentra-
tion. Interestingly, the previously active electron-rich cate-
chols were inactive under these conditions (Figure S5). In
contrast, LecA inhibition of catechols carrying electron
withdrawing substituents, such as nitrile 3, nitro 12, and
ketone 21, has not changed in presence of 2-mercaptoethanol
and over time (Table 1, Table 2).
At a concentration of 4 mM, ten out of the 30 catechols
tested showed a quantifiable and 2-mercaptoethanol-inde-
pendent inhibition of LecA in this competitive binding assay
(Table 1, Table 2, Figure 2 A). Benzoylcatechol 23 was the
most active compound with an inhibition of 39%. Docking of
23 into the LecA binding site suggests that the benzoyl ring
can interact with Gln53 (Figure S3A). In the competitive
binding assay, this compoundQs activity is followed by nitro-
catechol 12 and cyanocatechol 3 with inhibition of 33% and
23%, respectively. All three compounds were two- to fourfold
more active than the initial in silico hit, isobutyryl catechol 21
(11 % inhibition). Even though some of the catechols, such as
4-parachlorobenzoyl catechol (24), were only soluble at the
test concentration of 4 mM in presence of 25 % DMSO as
a cosolvent, LecA bound successfully to the Cy5 galactoside
S7 and 24 showed 22% inhibition of LecA. These results
support the notion that electron-deficient catechols can either
allosterically inhibit the LecA-galactoside interaction or
competitively bind to its carbohydrate-binding site.
Secondary Assays Verifying Binding of Catechols to LecA.
First, a subset of electron-rich and electron-deficient
catechols was tested in a thermal shift assay to verify their
interaction with LecA. In case of a ligand binding event, the
thermal stability of a protein increases due to stabilizing
interactions in the ligated state.[24] Therefore, the melting
point of LecA was measured in absence of ligand (Tm 89.4 8C),
in presence of a galactoside (Tm 91.1 8C) or thirteen catechols
(Figure S6).
A general trend could be observed where the electron-
deficient catechols, that is, nitriles 3 and 9, acetyl 17,
isobutyryl 21 and benzoyl 23, led to an increase of the melting
point of LecA. In particular, 4-benzoyl catechol 23 and 3-
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DT [K] Efficiency [%]
at 1 mM
CSP of W42 [ppm]
17 1197-09-7 Me H H 11:3 10:3 + 0.5 14.4 0.035
18 99-50-3 OH H H none none – 5.0 n.s.
19 99-40-1 CH2Cl H H inconcl. none – 22.8 0.095
20 3943-89-3 OEt H H none none – 9.0 n.s.
21 5466-89-7 iPr H H 10:2 11:2 + 0.35 9.0 0.08
22 62-13-5 (CH2)2NHMe*HCl H H inconcl. insoluble – 9.6 0.065
23 10425-11-3 Ph H H 39:5 39:3 + 0.36 50.9 0.110
24 134612-84-3 pCl-C6H4- H H 29:3* 22:2* – insoluble 0.185
25 61445-50-9 2,4-(HO)2-C6H3- H H 14:5 13:2 inconcl. 61.8 0.105
26 52479-85-3 3,4,5-(HO)3-C6H2- OH H inconcl.* inconcl.* – 142.6 0.125
27 1143-72-2 Ph OH H inconcl. inconcl. – 13.2 at 0.5 mM 0.045
28 31127-54-5 pHO-C6H4- OH H inconcl. inconcl.* – 38.5 0.035
29 5995-86-3 OH H OH inconcl. none – 24.0 n.s.
30 3856-05-1 OCH2
iPr H OH 8:2 8:1 – 16.4 0.055
Protein-observed 19F (PrOF) NMR spectroscopy was performed with 5FW-LecA. FP averages and std. dev. from 3 experiments, TSA averages from two
experiments, *= tested at 25 % DMSO, 2ME =2-mercaptoethanol, CSP= chemical shift perturbation, n.s. = not significant, std. dev. <0.03 ppm.
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cyano catechol 3 had the largest effect on the melting point of
LecA with an increase of + 0.4 8C and + 1.8 8C, respectively
(Tables 1, 2, Figure S6). In contrast, the electron-rich cat-
echols (methyl 11 and tert-butyl 13) and the unsubstituted
catechol 1 destabilized LecA and thus, lowered its melting
temperature. A strong destabilization was observed in case of
4-tert-butyl catechol 13 (@15.4 8C) and 4-methyl catechol 11
(@11.0 8C).
As an orthogonal binding assay ligand-observed NMR
spectroscopy experiments monitoring the T11 relaxation of
the electron-deficient catechol, virtual screening hit isobutyr-
yl 21, and the electron-rich catechol 4-tert-butyl catechol 13
were measured. The T11 relaxation rates of a small molecule
depend on its correlation time and hence can be used to
detect binding to higher molecular weight receptors.[25]
Therefore, T11 relaxation of isobutyryl catechol 21 or tert-
butyl catechol 13 were measured in presence and absence of
LecA, and both compounds showed an increase in relaxation
with LecA (Figure 2B, Figure S7). However, the relaxation
rate of isobutyryl catechol 21 was strongly increased in
presence of LecA (red) and could be fully reversed to the free
state in presence of an excess of Me-a-d-Gal (blue). The
effect of tert-butyl catechol 13 with LecA was much weaker
and addition of Me-a-d-Gal had no significant effect. Since
the binding of isobutyryl catechol 21 to LecA can be fully
competed with a galactoside, this data suggests that electron-
deficient catechols bind LecA in the carbohydrate-binding
site. Moreover, this result is in agreement with our compet-
itive binding assay with a fluorescent tracer, where isobutyryl
catechol 21 inhibited LecA and the inhibition of tert-butyl
catechol 13 was unspecific and absent in presence of
a scavenging nucleophile.
Both assays, T11 relaxation NMR spectroscopy and the
thermal shift assay, have further validated electron-deficient
catechols as ligands of LecA and NMR gave strong hints for
a direct galactose-competition as mode of action. Next, we
quantified the catecholsQ binding affinity using surface
plasmon resonance (SPR) as an orthogonal method and
localized their binding site by protein-observed NMR spec-
troscopy and X-ray crystallography.
Quantification of direct catechol binding to LecA was
performed using SPR analysis. Binding analyses were per-
formed by injecting various catechols at two concentrations
(0.2 and 1 mM, except for 16 and 27 which were injected at 0.2
and 0.5 mM). We identified 14 catechol hits by SPR, six of
which were in agreement with other biophysical assays (nitrile
3, hydroxymethyl 6, nitro 12, acetyl 17, benzoyl 23 and
dihydroxybenzoyl 25, Figure 3A, Figure S8). Subsequently,
multicycle kinetic analyses were performed on these six
prioritized hits to obtain the corresponding dissociation
constants (Kd) (Figure 3B, Figure S9). These data showed
that hydroxymethyl 6, acetyl 17 and dihydroxybenzoyl 25
have very weak affinity towards LecA (extrapolated Kd of
> 100 M) (Figure S9), whereas compounds nitrile 3, nitro 12
and benzoyl 23 catechols have promising Kd values in the low
millimolar range (Figure 3). The lowest Kd value was obtained
for nitro 12 (Kd = 0.56: 0.34 mM) followed by nitrile 3 (Kd =
1.11: 0.07 mM) and the most active compound in the
competitive binding assay, benzoyl 23, was somewhat less
active (Kd = 3.46: 0.41 mM). Finally, the initial virtual
screening hit isobutyryl 21 had a Kd of approx. 145 M
corresponding to the results from the competitive binding
assay. For weaker binding hits, the efficiency was used for
comparison of the affinity, among which 26 showed the
highest efficiency (142.6%), which is suspiciously high for
a small molecule. We hypothesized that this unexpected high
binding response observed on SPR is due to a potential
oxidation and unspecific interaction with the protein.
Protein-Observed NMR Reveals Catechols Targeting the
Carbohydrate-Binding Site of LecA
Protein-observed 19F (PrOF) NMR spectroscopy is a sen-
sitive technique to spot weak binders in a low millimolar
affinity range. Here, we used previously established PrOF
NMR with 5-fluorotryptophan-labeled (5FW)-LecA[26] to
determine the binding region of catechols. First, we measured
5FW-LecA in presence of para-nitrophenyl b-d-galactoside
(pNPGal) as well-known ligand for the carbohydrate-binding
Figure 2. Analysis of catechol binding to LecA using: A) a competitive
binding assay based on fluorescence polarization with catechols 3, 12,
17, 21, 23 and 25 and methyl a-d-galactoside as positive control;
B) T11 relaxation NMR spectroscopy of isobutyryl catechol 21 and tert-
butyl catechol 13. Signal intensity decay of methyl protons plotted for
21 and 13 vs. spin-lock times.
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site of LecA. As expected, the resonance of the 5-fluoro-
tryptophan located in the carbohydrate-binding site, W42,
showed a clear chemical shift perturbation (CSP) towards
a ligand-bound form in presence of pNPGal indicating that
PrOF NMR can be used to spot the binding site of ligands
(Figure 4).
Next, we validated 30 catechols in PrOF NMR (Table S2)
and observed the perturbation of W42 in presence of 18
catechols that target the carbohydrate-binding site (Fig-
ure S10). Notably, the chemical shift perturbation of W42 in
presence of the electron-deficient benzoyl catechol 23 was
comparable to pNPGal (Figure S11) and nitrile 3 also induced
a chemical shift perturbation of the W42 resonance (Fig-
ure 4).
We further analyzed uniformly 15N-labelled LecA in
1H,15N TROSY NMR experiments in presence and absence
of two galactosides or four catechols (Figure 4). The finger-
print of the resulting chemical shift perturbations was highly
similar for d-Gal and pNPGal compared to the three tested
catechols 3, 23 and 25 (Figure 4).
Taken together, compounds nitrile 3 and benzoyl 23 show
a comparable binding of LecA in protein-observed NMR
spectroscopy as the positive control pNPGal allowing us to
Figure 3. SPR analysis of catechol direct binding to LecA. A) The binding responses at steady state on the sensorgrams, when 0.2, 0.5 or 1 mM of
catechols were injected (blue, orange and black dots, respectively), were plotted against injection cycles of compounds. Dose-response increases
more than twofold are indicated by dotted circles. The catechol entries corresponding to the dose-response binding are indicated. Positive control
(0.1 mM pNPGal represented by crosses) was injected to monitor the activity of immobilized LecA and enable data normalization. B) Multi-cycle
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hypothesize that both compounds target the carbohydrate-
binding site of LecA.
X-Ray Crystallography Reveals Glycomimetic Binding Mode of
One Catechol Hit
To further investigate the interaction between the cat-
echol hits and LecA at atomic resolution, we co-crystallized
LecA with the six hits that were identified among all
biophysical assays, nitrile 3, hydroxymethyl 6, nitro 12, acetyl
17, benzoyl 23 and dihydroxybenzoyl 25. We adapted a dry co-
crystallization approach previously reported by Gelin et al.,
which involves deposition of the compound onto the crystal-
lization slide and gentle evaporation of DMSO prior to
dispensing the protein onto the dried compound.[27] This
approach enables the deposition of high amounts of the dried
compounds onto the slide, whilst avoiding complicated crystal
manipulation and use of high DMSO concentrations. Protein
crystals were obtained for co-crystallization of LecA with
nitrile 3, benzoyl 23 and dihydroxybenzoyl 25. X-ray diffrac-
tion data were collected from crystals of LecA in complex
with nitrile 3 (LecA-3) and in complex with dihydroxybenzoyl
25 (LecA-25) whereas the crystals of LecA with benzoyl 23
diffracted poorly (resolution > 4 c) and were not further
investigated. Both complex structures were successfully
solved at 1.84 c in space group I 2 (for LecA-3) and P21221
(for LecA-25) (Table S3).
The overall structure of LecA-25 is very similar to LecA-
galactose (global RMSD = 0.29 c). Intriguingly, the electron
density corresponding to compound 25 was found remotely
from the galactose binding site (Figure S12A), which was
unexpected considering its ability to outcompete the galac-
tose-derived fluorescent probe. We hypothesized that the
interaction of 25 with the remote site on LecA maybe
a crystallization artefact since the molecule locates at the
interface of the protein crystal contacts and forms only
minimal interactions with the protein (Figure S12B).
The LecA-3 structure is also very similar to the LecA-
galactose complex (PDB: 1OKO) with a global RMSD of
0.8 c (superposition of equivalent Ca atoms). Here, however,
catechol 3 occupies the previously reported galactose binding
site in monomers A and C of the LecA tetramer (Figure 5A
and B). The two vicinal hydroxy groups of 3 coordinate the
Ca2+ ion and form hydrogen-bonded interactions with the
side chains of Asp100 and Asn107 and the backbone oxygen
of Tyr36 (Figure 5 D), the interaction of which imitates the
roles of OH3 and OH4 of galactose in the LecA-galactose
interaction (Figure 5 C). A conserved water molecule
(WAT1) forms hydrogen bond bridges between the nitrogen
atom of the nitrile in catechol 3 and the oxygen atom the
carbonyl group of Pro51 (Figure 5 D). The nitrogen atom thus
assumes the role of OH6 in the LecA-galactose interaction,
where hydrogen bond bridges through WAT1 were identified
between the OH6 group and Pro51 (Figure 5C). Shifting the
nitrile group to the neighboring carbon atom, that is, to
Figure 4. (left) Protein-observed 19F (PrOF) NMR spectroscopy of nitrile 3 and pNPGal with 5FW-LecA; (right) 1H,15N TROSY-HSQC NMR spectra
(upper panel) of uniformly 15N-labelled LecA in absence and presence of ligands d-Gal, pNPGal or nitrile 3 and a plot with a 1:0 barcode (bottom
panel) shows CSPs and changes in peak intensity of arbitrarily numbered resonances in LecA observed for ligands d-Gal, pNPGal, nitriles 3, 9,
benzoyl 23 and dihydroxybenzoyl 25. This data indicated catechols 3, 9, 23, 25 bind LecA in a region similar to d-Gal and pNPGal suggesting
binding to the carbohydrate-binding site of LecA.
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position R2 in compound 9 instead of position R1 in
compound 3, resulted in approximately a threefold-reduction
of the SPR efficiency and inhibition in the FP assay (Table 1),
which further substantiates the essence of the positioning and
the role of the nitrile group in the LecA-3 interaction.
To investigate if catechols interact with other Ca2+-
binding lectins and could be used as a general motif for
glycomimetics, we performed 1H-15N HSQC NMR with 15N-
labeled Langerin CRD (Figure 6A). We observed that 3
promoted chemical shift perturbations (CSPs) of amino acids
located in the carbohydrate-binding site of Langerin (Fig-
ure 6B), but also affected amino acids that are located at
a certain distance. The magnitude of CSPs observed for 3
(tested at 1 mM due to solubility restrictions) was generally
weaker than mannose which was tested at 30 mM. Given the
allosteric nature of some calcium binding lectins such as
Langerin,[16a, 28] changes in the resonances located far away
from the carbohydrate-binding site can be correlated to
changes in the binding site. Potentially, 3 can be located in the
binding site, or in a remote site that triggers the allosteric
network.
To demonstrate that 3 targets the carbohydrate-binding
site of Langerin, we performed 1H STD competition NMR
experiments (Figure 6C). For this, we recorded STD spectra
of 3 without or with Langerin ECD and upon addition of
mannose as the competitor. As result, we observed a 65%
reduction in peak intensities of resonances from compound 3
in STD NMR spectra in presence of mannose indicating its
partial competition from the carbohydrate-binding. This is in
agreement with 1H-15N HSQC data, where 3 has been
observed to alter resonances from both the carbohydrate-
and secondary binding sites in Langerin. Thus, these data
reveal catechol 3 as a general glycomimetic motif for
a bacterial and a mammalian calcium-binding lectin.
Conclusion
In this work, a non-carbohydrate glycomimetic has been
identified for a relevant anti-infective drug target. We have
established catechols as mimicry of the carbohydrate ligand,
binding to the protein via the crucial calcium-ion present in
the carbohydrate-binding site of LecA, a key lectin involved
in infection mechanisms of the ESKAPE pathogen P.
aeruginosa. Therefore, the catechols have good potential
beyond LecA and may also serve as glycomimetics for the
large family of animal C-type lectins and other bacterial
lectins relying on calcium-mediated glycan recognition.
Target specificity required for a selective drug can be
achieved by further optimizing a central catechol motif
addressing the carbohydrate-binding site.
Despite the widespread belief, catechols are not necessa-
rily PAINS when care is taken in analysing their binding
properties in orthogonal assays under appropriate experi-
mental conditions. We showed that electron-deficient cat-
echols are stable under the conditions tested and their
interaction with LecA has been confirmed in several orthog-
onal assays. In contrast, electron-rich catechols proved to be
unspecific binders and their observed effect on LecA could be
reversed in presence of a competing nucleophile, 2-mercap-
toethanol.
Figure 5. A) Overall structure of LecA-3 complex (PDB code: 6YO3). 2 molecules of compound 3 are shown as sticks and the Ca2+ ions as green
spheres. Dotted circles indicate the binding sites of 3. Each LecA monomer is depicted as cartoon in different colors. B) Surface display of
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From an initial virtual screening approach for the
bacterial lectin LecA, we have identified electron-deficient
catechols as non-carbohydrate inhibitors for the lectin LecA.
We validated our hits in various orthogonal biophysical
assays. The binding of the initial catechol hit isobutyryl 21
derived from virtual screening was confirmed in a competitive
binding assay based on fluorescence polarization. This assay
and a thermal shift assay were used to demonstrate that only
catechols with electron-withdrawing groups are robust inhib-
itors of LecA, while catechols with electron-donating sub-
stituents showed protein destabilization and unspecific in-
hibition which was absent in presence of a nucleophilic
scavenger. This specificity of catechols was further confirmed
in ligand-observed T11-relaxation NMR experiments for
electron-deficient isobutyryl catechol 21 and electron-rich 4-
tert-butylcatechol 13. The binding affinity of catechols was
determined by SPR and led to Kd-values in the millimolar
range, for example, nitrile 3 with a Kd of 1.11: 0.07 mM and
nitro 12 with a Kd of 0.56: 0.34 mM. These affinities of the
fragment hits (MW 135–155 gmol@1) result in ligand efficien-
cies of 0.40 for both compounds, providing a good basis for
future fragment growing. 19F-protein observed NMR spec-
troscopy revealed that the catechols with electron-withdraw-
ing substituents were binding to the carbohydrate-binding site
of LecA. Finally, X-ray analysis of LecA in complex with
nitrile 3 unambiguously confirmed catechols as galactose-
mimicking ligands located in the carbohydrate-binding site.
The structure revealed that catechols were coordinating to the
calcium ion via their vicinal hydroxy groups, and the nitrile
group underwent a hydrogen-bonding interaction with a crys-
tal bound water molecule, highly homologous to the primary
hydroxy group of galactose in complex with LecA.
This work sets the basis for future optimization of the
catechol scaffold to increase binding potency and drug-like
properties of a possible antimicrobial agent. Therefore, this
work sets a new starting point for the development of future
Figure 6. A) 1H-15N HSQC NMR spectra of uniformly 15N-labelled human Langerin CRD in absence of ligands (grey) and in presence of mannose
(red) or catechol 3 (blue). The two resonances K257 and K299 are magnified and shown as an example for the interaction of 3 (blue) with
Langerin, which is in the similar manner to mannose (red). B) The perturbed resonances in the CSP plot (CSP >0.005 p.p.m., for correlation of
resonance ID and amino acid see Table S4) were used for mapping the binding site of 3 on a structure of Langerin CRD (PDB: 3P5D). K257 and
K299 are highlighted in the CSP plot as 1 and 87, respectively. C) The competition 1H STD NMR experiment with mannose was performed with 3
in presence and absence of Langerin ECD. Binding of 3 to the carbohydrate-binding site of Langerin has been confirmed as indicated by
decreasing peak intensities in the STD NMR spectrum upon addition of mannose.
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LecA inhibitors against biofilm-associated P. aeruginosa
infections by developing new non-carbohydrate LecA glyco-
mimetics and provides a structure-based rationale for the
development of lectin-inhibitors in general.
Moreover, catechol 3 proved to target the carbohydrate-
binding site of both Ca2+-binding bacterial (LecA) and
mammalian (Langerin) lectins. Given that Ca2+-binding
lectins have been considered “undruggable” for a long
time,[29] we believe catechols challenge this paradigm as
a novel class of non-carbohydrate glycomimetics. Further
growing of this low affinity fragment hit, catechol 3, into lead
structures will provide high target affinity. Structure-based
design of additional functional groups will provide the
specificity towards the lectin of interest for the desired
indication.
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